Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…